300832 Stock Overview
Engages in the research, development, production, and sale of clinical laboratory instruments and in vitro diagnostic reagents to hospitals in China and internationally. More details
| Snowflake Score | |
|---|---|
| Valuation | 5/6 |
| Future Growth | 5/6 |
| Past Performance | 4/6 |
| Financial Health | 6/6 |
| Dividends | 3/6 |
My Notes
Capture your thoughts, links and company narrative
Shenzhen New Industries Biomedical Engineering Co., Ltd. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | CN¥61.14 |
| 52 Week High | CN¥97.20 |
| 52 Week Low | CN¥58.31 |
| Beta | -0.41 |
| 1 Month Change | -7.74% |
| 3 Month Change | -10.09% |
| 1 Year Change | -16.88% |
| 3 Year Change | 40.94% |
| 5 Year Change | n/a |
| Change since IPO | 157.00% |
Recent News & Updates
Shenzhen New Industries Biomedical Engineering Co., Ltd.'s (SZSE:300832) Intrinsic Value Is Potentially 36% Above Its Share Price
Jan 13
Investors Don't See Light At End Of Shenzhen New Industries Biomedical Engineering Co., Ltd.'s (SZSE:300832) Tunnel
Dec 15Investors Shouldn't Overlook The Favourable Returns On Capital At Shenzhen New Industries Biomedical Engineering (SZSE:300832)
Nov 17Recent updates
Shenzhen New Industries Biomedical Engineering Co., Ltd.'s (SZSE:300832) Intrinsic Value Is Potentially 36% Above Its Share Price
Jan 13Investors Don't See Light At End Of Shenzhen New Industries Biomedical Engineering Co., Ltd.'s (SZSE:300832) Tunnel
Dec 15Investors Shouldn't Overlook The Favourable Returns On Capital At Shenzhen New Industries Biomedical Engineering (SZSE:300832)
Nov 17Should You Be Adding Shenzhen New Industries Biomedical Engineering (SZSE:300832) To Your Watchlist Today?
Oct 14Shenzhen New Industries Biomedical Engineering Co., Ltd. (SZSE:300832) Just Released Its Second-Quarter Results And Analysts Are Updating Their Estimates
Aug 25A Look At The Intrinsic Value Of Shenzhen New Industries Biomedical Engineering Co., Ltd. (SZSE:300832)
Jul 01Here's Why We Think Shenzhen New Industries Biomedical Engineering (SZSE:300832) Might Deserve Your Attention Today
Apr 09The Returns On Capital At Shenzhen New Industries Biomedical Engineering (SZSE:300832) Don't Inspire Confidence
Mar 18Estimating The Fair Value Of Shenzhen New Industries Biomedical Engineering Co., Ltd. (SZSE:300832)
Mar 01Shareholder Returns
| 300832 | CN Medical Equipment | CN Market | |
|---|---|---|---|
| 7D | -1.5% | 3.2% | 3.5% |
| 1Y | -16.9% | -10.2% | 10.9% |
Return vs Industry: 300832 underperformed the CN Medical Equipment industry which returned -10.2% over the past year.
Return vs Market: 300832 underperformed the CN Market which returned 10.9% over the past year.
Price Volatility
| 300832 volatility | |
|---|---|
| 300832 Average Weekly Movement | 5.4% |
| Medical Equipment Industry Average Movement | 5.7% |
| Market Average Movement | 7.1% |
| 10% most volatile stocks in CN Market | 11.1% |
| 10% least volatile stocks in CN Market | 4.2% |
Stable Share Price: 300832 has not had significant price volatility in the past 3 months compared to the CN market.
Volatility Over Time: 300832's weekly volatility (5%) has been stable over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 1995 | 2,627 | Wei Rao | www.snibe.com |
Shenzhen New Industries Biomedical Engineering Co., Ltd., engages in the research, development, production, and sale of clinical laboratory instruments and in vitro diagnostic reagents to hospitals in China and internationally. It offers immunoassay machine, biochemistry/electrolyte, integrated system, lab automation, molecular diagnostics, and rapid test solutions. The company was founded in 1995 and is based in Shenzhen, China.
Shenzhen New Industries Biomedical Engineering Co., Ltd. Fundamentals Summary
| 300832 fundamental statistics | |
|---|---|
| Market cap | CN¥48.04b |
| Earnings (TTM) | CN¥1.85b |
| Revenue (TTM) | CN¥4.44b |
26.0x
P/E Ratio10.8x
P/S RatioIs 300832 overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| 300832 income statement (TTM) | |
|---|---|
| Revenue | CN¥4.44b |
| Cost of Revenue | CN¥1.20b |
| Gross Profit | CN¥3.23b |
| Other Expenses | CN¥1.38b |
| Earnings | CN¥1.85b |
Last Reported Earnings
Sep 30, 2024
Next Earnings Date
Apr 18, 2025
| Earnings per share (EPS) | 2.36 |
| Gross Margin | 72.86% |
| Net Profit Margin | 41.72% |
| Debt/Equity Ratio | 0% |
How did 300832 perform over the long term?
See historical performance and comparisonDividends
1.6%
Current Dividend Yield42%
Payout RatioCompany Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2025/01/18 22:42 |
| End of Day Share Price | 2025/01/17 00:00 |
| Earnings | 2024/09/30 |
| Annual Earnings | 2023/12/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .
Analyst Sources
Shenzhen New Industries Biomedical Engineering Co., Ltd. is covered by 20 analysts. 15 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| Pei Cheng | China Galaxy Securities Co., Ltd. |
| Jin Zhang | China International Capital Corporation Limited |
| Zhu Chen | Citic Securities Co., Ltd. |